Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026

20 hours ago 4

Maham Fatima

Wed, December 31, 2025 astatine 10:25 AM CST 2 min read

Gilead Sciences Inc. (NASDAQ:GILD) is 1 of the best stocks for the adjacent decade. On December 12, Morgan Stanley raised the firm’s terms people connected Gilead to $151 from $147 with an Overweight standing connected the shares. The steadfast informed investors that the regulatory and governmental uncertainties presently weighing connected biopharma are expected to subside. As these argumentation overhangs fade, Morgan Stanley anticipates a displacement successful marketplace attraction backmost to the industry’s halfway fiscal and operational performance.

Later, connected December 15, Gilead Sciences Inc. (NASDAQ:GILD) announced affirmative topline results from its Phase 3 ARTISTRY-2 objective trial. The survey demonstrated that an investigational once-daily, single-tablet regimen combining bictegravir (75 mg) and lenacapavir (50 mg), referred to arsenic BIC/LEN, is statistically non-inferior to the existent standard-of-care, BIKTARVY. This proceedings focused connected virologically suppressed adults with HIV-1 who switched from BIKTARVY to the caller combination, gathering the superior efficacy endpoint of maintaining HIV-1 RNA levels beneath 50 copies/mL astatine Week 48.

Morgan Stanley Expects Gilead Sciences (GILD) to Thrive arsenic Biopharma Policy Uncertainties Fade successful 2026

Gilead plans to usage the results from ARTISTRY-2 alongside information from the ARTISTRY-1 trialwhich announced akin non-inferiority results successful November, arsenic the instauration for upcoming regulatory submissions. The institution aims to contiguous elaborate findings astatine a aboriginal technological congress. These advancements correspond a important measurement successful Gilead’s 35-year past of HIV innovation, perchance offering a new, simplified attraction enactment for the millions of radical surviving with the microorganism globally.

Gilead Sciences Inc. (NASDAQ:GILD) is simply a biopharmaceutical institution that discovers, develops, and commercializes medicines successful the areas of unmet aesculapian request successful the US, Europe, and internationally.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.